EFFICACY AND SAFETY OF DUAL INTERLEUKIN-17A AND INTERLEUKIN-17F INHIBITION WITH BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 RANDOMISED CONTROLLED TRIAL
Main Article Content
Keywords
Psoriatic arthritis, Bimekizumab, Interleukin-17A and IL-17F, Biologic DMARDs and Phase 3 clinical trial
Abstract
Psoriatic arthritis is an autoimmune inflammatory disorder that is long-lasting and necessitates a treatment method that will manage both extra-articular and musculoskeletal signs or symptoms. This was a blinded phase 3, multicentre, randomised, controlled trial that assessed efficacy and safety of bimekizumab encompassing dual interleukin-17A and interleukin-17F in biologic-naive patients with active psoriatic arthritis. The randomisation was done among 640 patients to receive bimekizumab 160 mg after every four weeks, placebo, or reference adalimumab. The major outcome was the accomplishment of an American College of Rheumatology 50 percent improvement (ACR50) after Week 16. Bimekizumab showed a greater ACR50 response when compared to placebo with the improvements in joint, skin, functional, and quality-of-life outcomes persisting at Week 24. The safety profile was also in line with the interleukin-17 pathway inhibition, and the most frequent adverse events reported were infections and mucocutaneous candidiasis. In general, bimekizumab was associated with a fast, sustained, and comprehensive control of the disease with a satisfactory safety profile.
References
2. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet 2018; 391: 2273–84.
3. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18: 465–79.
4. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020; 79: 700–12.
5. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis 2018; 77: 523–32.
6. Liu S, Song X, Chrunyk BA, et al. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun 2013; 4: 1888.
7. Blair HA. Secukinumab: a review in psoriatic arthritis. Drugs 2021; 81: 483–94.
8. O’Rielly DD, Rahman P. A review of ixekizumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol 2018; 14: 993–1002.
9. Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol 2020; 11: 1894.
10. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med 2021; 385: 142–52.
11. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021; 397: 487–98.
12. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med 2021; 385: 130–41.
13. Coates LC, McInnes IB, Merola JF, et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its openlabel extension study. Arthritis Rheumatol 2022; published online July 13. https://doi.org/10.1002/art.42280.
14. Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet 2020; 395: 427–40.
15. Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 2022; published Dec 7. https://doi.org/10.1016/S0140- 6736(22)02303-0.
16. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–73
17. van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005; 64 (suppl 2): ii61–64.
18. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (suppl 2): ii49–54.
19. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2015; 386: 1137–46.
20. Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther 2018; 20: 47.
21. Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis 2018; 77: 890–97.
22. Ogdie A, Michaud K, Nowak M, et al. Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open 2020; 6: e001321.
23. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149–62.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Rajesh Ponugupati
Assistant Professor, Department of Orthopaedics, Nimra Institute of Medical Sciences, Andhra Pradesh, India.
